For decades, biotech manufacturing thrived on globalization. A molecule might be discovered in Boston, scaled in Singapore, and filled and finished in Ireland — all part of an intricate web optimized for cost efficiency and global reach. But that same system also revealed its fragility: pandemic disruptions, geopolitical frictions, and raw-material shortages exposed how dependent biopharma supply chains had become on far-flung partners.
Now, the industry is trending toward onshoring, or bringing production closer to home. It’s a deliberate, long-term repositioning of how innovation moves from lab to large-scale production. The decision isn’t simple: building or expanding U.S. capacity requires new capital, talent, and operational design. But for many companies, the calculus has changed in ways that make the case for onshoring stronger than ever.
This article explores why that shift is happening and what it looks like on the ground.
Why the Calculus Has Changed
The past five years have reshaped the global manufacturing equation. COVID-era supply shocks made plain the vulnerability of just-in-time models that relied on cross-border transport. Add to that rising geopolitical tensions, the growing complexity of biologics, and a policy environment encouraging domestic production — and the old cost-benefit assumptions start to fall apart.
- Economic and operational pressures
- The original rationale for offshoring, like low labor costs and access to large-scale facilities, has narrowed. Advanced automation, single-use technologies, and digital twins are leveling the playing field. A plant in North Carolina or Texas can now achieve labor efficiency once available only overseas, while maintaining tighter control over intellectual property and quality systems.
- Policy tailwinds
- U.S. industrial policy has moved decisively toward domestic biomanufacturing. The CHIPS and Science Act channels funding into use-inspired R&D and regional innovation (including biotechnology) through the NSF’s Technology, Innovation, and Partnerships (TIP) directorate and Regional Innovation Engines program. State programs, from North Carolina’s Job Development Investment Grant (JDIG) to the Texas Enterprise Fund and Pennsylvania’s Keystone Innovation Zone tax credits, layer on performance-based incentives that can materially shift project economics.
- U.S. industrial policy has moved decisively toward domestic biomanufacturing. The CHIPS and Science Act channels funding into use-inspired R&D and regional innovation (including biotechnology) through the NSF’s Technology, Innovation, and Partnerships (TIP) directorate and Regional Innovation Engines program. State programs, from North Carolina’s Job Development Investment Grant (JDIG) to the Texas Enterprise Fund and Pennsylvania’s Keystone Innovation Zone tax credits, layer on performance-based incentives that can materially shift project economics.
- Speed and market proximity
- In an era where first-mover advantage can define the commercial success of a therapy, domestic manufacturing offers a critical edge. Shorter logistics chains mean faster turnaround from batch release to clinical or commercial delivery. It also strengthens relationships with regulators and payers who increasingly prioritize domestic resilience in their risk assessments.
- In an era where first-mover advantage can define the commercial success of a therapy, domestic manufacturing offers a critical edge. Shorter logistics chains mean faster turnaround from batch release to clinical or commercial delivery. It also strengthens relationships with regulators and payers who increasingly prioritize domestic resilience in their risk assessments.
- The resilience premium
- Boards and investors increasingly accept higher near-term costs for greater supply-chain control and reliability, treating resilience as a strategic investment rather than a pure expense.
What onshoring actually looks like in practice
Onshoring is not a single move, it’s a spectrum of strategic reconfigurations. For some, it’s relocating key process steps; for others, it’s designing entire facilities from the ground up. The pattern emerging across biotech is one of selective, high-value repatriation rather than wholesale relocation.
High-value, high-risk segments such as cell- and gene-therapy production, critical active pharmaceutical ingredients (APIs), and early-phase clinical manufacturing are leading the return. These products demand tight process control, rapid iteration, and regulatory visibility — advantages that are difficult to sustain across multiple time zones and jurisdictions. Some other trends include:
- New facility models
- The next generation of onshore plants looks very different from the monolithic biomanufacturing campuses of the past. Modular, flexible, and technology-enabled facilities dominate current investment pipelines. Options such as Cytiva’s KUBio or G-CON’s POD cleanrooms can compress delivery to roughly 6–18 months for defined scopes, whereas traditional stick-built projects commonly run 15–30 months from concept to commissioning. Single-use bioreactors reduce cleaning-validation time, and integrated analytics enable predictive maintenance and quality assurance.
- The next generation of onshore plants looks very different from the monolithic biomanufacturing campuses of the past. Modular, flexible, and technology-enabled facilities dominate current investment pipelines. Options such as Cytiva’s KUBio or G-CON’s POD cleanrooms can compress delivery to roughly 6–18 months for defined scopes, whereas traditional stick-built projects commonly run 15–30 months from concept to commissioning. Single-use bioreactors reduce cleaning-validation time, and integrated analytics enable predictive maintenance and quality assurance.
- Geographic clustering
- Established life science hubs like Boston-Cambridge, the San Francisco Bay Area, and the Research Triangle continue to attract anchor investments, but secondary clusters are rising fast. Texas’s Innovation Corridor, the greater Philadelphia cell-therapy region, and emerging sites in Indiana and Utah are offering competitive incentives and university partnerships to draw mid-size manufacturers.
- Established life science hubs like Boston-Cambridge, the San Francisco Bay Area, and the Research Triangle continue to attract anchor investments, but secondary clusters are rising fast. Texas’s Innovation Corridor, the greater Philadelphia cell-therapy region, and emerging sites in Indiana and Utah are offering competitive incentives and university partnerships to draw mid-size manufacturers.
- Operational transformation
- Domestic sites often embrace higher levels of automation and data integration. From electronic batch records to AI-driven scheduling, these plants can operate with leaner teams while maintaining compliance and throughput. They’re also rethinking inventory strategy: where global networks once relied on just-in-time logistics, many onshore operations now balance efficiency with localized buffer inventory to absorb shocks.
What’s not coming back and why
Some high-volume, cost-sensitive steps may remain global for now. Many leaders are deliberately keeping diversified footprints to balance cost, risk, and capacity across regions. Maintaining a mix of domestic and international partners isn’t a weakness—it’s strategic optionality.
The real implementation challenges
While the strategic logic of onshoring is sound, execution is anything but simple. Companies embarking on this transition face a series of practical, financial, and regulatory hurdles that can make or break the effort.
- Talent and expertise
- One of the most immediate barriers is workforce availability. Building an advanced biologics facility demands specialized engineers, validation experts, and automation technicians, which are roles already in short supply. Many companies are investing in regional training partnerships with universities or leveraging hybrid models that combine in-house staff with expert consultants.
- One of the most immediate barriers is workforce availability. Building an advanced biologics facility demands specialized engineers, validation experts, and automation technicians, which are roles already in short supply. Many companies are investing in regional training partnerships with universities or leveraging hybrid models that combine in-house staff with expert consultants.
- Capital and timelines
- Constructing even a modular GMP facility requires significant upfront investment and can take two to four years from site selection to validated production. In an industry where pipeline milestones drive valuation, bridging that gap requires disciplined project management and creative financing—often blending venture, debt, and public incentives.
- Constructing even a modular GMP facility requires significant upfront investment and can take two to four years from site selection to validated production. In an industry where pipeline milestones drive valuation, bridging that gap requires disciplined project management and creative financing—often blending venture, debt, and public incentives.
- Navigating incentives
- Federal and state programs can dramatically shift the economics of onshoring, but they’re fragmented and often complex to access. Some states offer refundable tax credits for R&D and capital expenditures; others provide grants tied to job creation or sustainability metrics. Companies must weigh the long-term compliance obligations of these programs against their immediate financial benefits.
- Federal and state programs can dramatically shift the economics of onshoring, but they’re fragmented and often complex to access. Some states offer refundable tax credits for R&D and capital expenditures; others provide grants tied to job creation or sustainability metrics. Companies must weigh the long-term compliance obligations of these programs against their immediate financial benefits.
- Supply-chain continuity
- Transitioning manufacturing locations without interrupting existing supply chains demands precision. Many firms adopt phased strategies like building pilot or clinical capacity domestically while maintaining commercial supply abroad until the new site is fully validated. The dual-site period can be resource-intensive but reduces operational risk.
- Transitioning manufacturing locations without interrupting existing supply chains demands precision. Many firms adopt phased strategies like building pilot or clinical capacity domestically while maintaining commercial supply abroad until the new site is fully validated. The dual-site period can be resource-intensive but reduces operational risk.
- Regulatory transition
- Any transfer of manufacturing involves meticulous regulatory engagement. Facilities must be inspected, validated, and approved under existing product licenses. Companies that plan early, harmonize quality systems, and maintain transparent communication with the FDA and EMA are more likely to avoid costly delays.
- Any transfer of manufacturing involves meticulous regulatory engagement. Facilities must be inspected, validated, and approved under existing product licenses. Companies that plan early, harmonize quality systems, and maintain transparent communication with the FDA and EMA are more likely to avoid costly delays.
At Harmony Biotech Consulting, we help clients navigate every step of the onshoring journey, from strategic modeling and site selection to regulatory validation and operational scale-up. With deep expertise across biotech manufacturing, regulatory affairs, and quality systems, our team empowers organizations to build the manufacturing ecosystems of tomorrow — stronger, smarter, and closer to home.